ReviewFrontiers in medicine2026
Crosstalk in the kidney-muscle axis: myokines and muscle-relevant mediators in chronic kidney disease-associated sarcopenia.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a systemic disorder in which sarcopenia serves as a critical driver of frailty and mortality. However, the "kidney-muscle axis" remains conceptually fragmented, often confounded by the overlapping definitions of protein-energy wasting (PEW) and cachexia. This review argues that CKD-associated sarcopenia is not driven by isolated myokines, but rather by a clearance-distorted, inflammation-coupled signaling network. We first disambiguate sarcopenia from PEW and cachexia, distinguishing canonical myokines from mediators whose interpretive value is altered by uremia. We then propose a framework organized around four pillars: hypercatabolism, anabolic resistance, mitochondrial dysfunction and bioenergetic remodeling, and context-dependent inflammatory signaling. Within this context, we reinterpret key mediators, including myostatin, growth differentiation factor 15 (GDF-15), insulin-like growth factor 1 (IGF-1), irisin, and interleukin-6 (IL-6), emphasizing that their circulating levels reflect a complex entanglement of altered secretion, impaired renal clearance, and tissue-specific resistance. While the kidney-to-muscle vector is well-supported, direct muscle-to-kidney feedback remains less established. By framing myokine dysregulation as a mechanistic interface, this review aims to refine causal inference and support the development of targeted therapies for muscle wasting in CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.